Table 1.
Demographic data, disease characteristics and medications at the time of the evaluation n (%)
| Overall (n = 99) | CD (n = 62) | UC (n = 37) | P value | |
| Gender, females | 59 (59.6) | 32 (51.6) | 27 (73.0) | 0.063 |
| Age (yr) | 12.8 ± 2.6 | 13.4 ± 2.4 | 11.6 ± 2.5 | 0.0011 |
| Age at diagnosis (yr) | 9.9 ± 3.1 | 10.7 ± 2.9 | 8.6 ± 3.0 | < 0.0011 |
| Number of hospitalizations4 | 2 (1-4) | 2 (1-4) | 3 (1-6) | 0.092 |
| Disease duration at IMPACT completion (yr) | 2.8 ± 2.6 | 2.7 ± 2.5 | 3.0 ± 2.7 | 0.481 |
| Disease activity | NA | 7.2 ± 10.3 | 14.0 ± 20.5 | NA |
| Disease status, in remission | 70 (70.7) | 45 (72.6) | 25 (67.6) | 0.653 |
| Physician global assessment | 0.93 | |||
| Clinical remission | 80 (80.8) | 50 (80.6) | 30 (81.1) | |
| Mild | 14 (14.1) | 9 (14.5) | 5 (13.5) | |
| Moderate | 5 (5.1) | 3 (4.8) | 2 (5.4) | |
| Medications at IMPACT completion | ||||
| Antibiotics | 2 (2.0) | 2 (3.2) | 0 (0.0) | 0.523 |
| Steroids | 39 (39.4) | 24 (38.7) | 15 (40.5) | 0.993 |
| Immunomodulators | 68 (68.7) | 47 (75.8) | 21 (56.8) | 0.113 |
| Biologic agents | 31 (31.3) | 25 (40.3) | 6 (16.2) | 0.033 |
| Enteral nutrition | 0 (0.0) | 0 (0.0) | 0 (0.0) | NA |
| Aminosalicylates | 52 (52.5) | 15 (24.2) | 37 (100.0) | < 0.0013 |
1
t-test;
2
Mann-Whitney test;
3
Fisher’s exact test;
4
Three months prior to completing IMPACT, median (interquartile range). NA: Not applicable; CD: Crohn’s disease; UC: Ulcerative colitis.